Doreen Chung, MD
Urogynecology and Reconstructive Pelvic Surgery · New Hyde Park, NYNPI 1215188214
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (53.6%), travel and lodging and consulting fees — rather than concentrated in one kind of arrangement. It is spread thinly across 22 manufacturers, the largest accounting for just 21.8%. Among urogynecology and reconstructive pelvic surgery clinicians in NY with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 210 payments — averaging $64.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Axonics, Inc.$3K
- Boston Scientific$3K
- AbbVie$2K
- Medtronic$1K
- Coloplast$897
- Sumitomo Pharma America, Inc.$767
- plus $3K from 16 others
Across 26 payments — averaging $7016.51 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$143K
- Idorsia Pharmaceuticals US Inc$22K
- Boston Scientific$17K
What the payments were for
- Consulting fees$2,73820%
- Speaking & faculty fees$6395%
- Travel & lodging$2,91522%
- Food & beverage$7,26454%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Axonics, Inc. | 20 | $2,961 |
| Boston Scientific | 18 | $2,927 |
| AbbVie(2 entities) | 31 | $1,970 |
| Medtronic(2 entities) | 16 | $1,182 |
| Coloplast | 17 | $897 |
| Sumitomo Pharma America, Inc. | 30 | $767 |
| Lumenis, Inc | 1 | $639 |
| Procept Biorobotics Corporation | 7 | $584 |
| Urovant Sciences Inc | 19 | $538 |
| Astellas Pharma US Inc | 21 | $396 |
| Cook Medical LLC | 7 | $277 |
| Hollister Incorporated | 6 | $122 |
| Pfizer | 4 | $65 |
| C. R. Bard, Inc. & Subsidiaries | 3 | $42 |
| Ambu Inc. | 1 | $37 |
| Rochester Medical Corporation | 2 | $34 |
| Johnson & Johnson | 2 | $25 |
| Tolmar Pharmaceuticals, Inc. | 1 | $24 |
| Urogen Pharma, Inc. | 1 | $19 |
| Dentsply IH Inc. | 1 | $18 |
| Antares Pharma, Inc. | 1 | $18 |
| Avadel Specialty Pharmaceuticals, LLC | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Axonics$2,636
- Bulkamid$2,614
- Capio RP$2,025
- BOTOX$1,269
- INTERSTIM$909
- ALTIS$571
- AquaBeam Robotic System$247
- Cook$190
- GEMTESA$150
- AQUABEAM SYSTEM$126
- GENERAL BPH$117
How this compares
$13,555 in reported general payments places this provider in the 90th percentile of 90 urogynecology and reconstructive pelvic surgery providers in New York.
See all urogynecology and reconstructive pelvic surgery providers in New York →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| GemtesaVibegron | 450 | $308,794 |
| MyrbetriqMirabegron | 149 | $101,636 |
| BotoxOnabotulinumtoxina | 52 | $42,197 |
| Estradiol | 294 | $17,828 |
| Mirabegron ErMirabegron | 17 | $10,739 |
| PremarinEstrogens, Conjugated | 11 | $4,841 |
| Trospium Chloride | 68 | $4,333 |
| Methenamine Hippurate | 24 | $1,694 |
| Tamsulosin Hcl | 103 | $1,588 |
| Fesoterodine Fumarate ErFesoterodine Fumarate | 12 | $991 |
| Finasteride | 62 | $925 |
| Oxybutynin Chloride ErOxybutynin Chloride | 13 | $464 |
| Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip | 15 | $338 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 34 | $316 |
| Ibuprofen | 17 | $230 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Sumitomo Pharma America, Inc.Gemtesa | $767 | $308,794450 claims |
| Astellas Pharma US IncMyrbetriq | $396 | $101,636149 claims |
| AbbVieBotox | $1,970 | $42,19752 claims |
| PfizerPremarin | $65 | $4,84111 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 90 urogynecology and reconstructive pelvic surgery providers in New York.
Other urogynecology and reconstructive pelvic surgery in New Hyde Park
- Robert MoldwinNew Hyde Park$35K
- Wai LeeNew Hyde Park$17K
- Jason KimStony Brook$346K
- Dara ShalomGreat Neck$94K
- Harvey WinklerGreat Neck$81K
- Nitya AbrahamBronx$24K
- Cornelius VerhoestPoughkeepsie$21K
- Abeer EddibCheektowaga$19K
- Jennifer HillRiverhead$13K
- Ido SirotaNew York$12K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.